Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE